The transition reflects Bio Ascend’s leadership of the next phase of development and growth for the workshops.
Recognizing Nia Beckley, MD, MEng, and Jordyn Silverstein, MD, MS, as rising physician-scientists shaping the future of cancer research and care
As Interim President, Cherie Myatt will provide executive leadership across the organization, reinforcing Vaniam Group’s long-term commitment to value creation.
Mr Tulk will spearhead innovative digital solutions, advanced analytics, and new offerings for Vaniam Group’s clients.
Ms Gott’s extensive background in hematology and solid tumors, as well as her biopharma experience, will drive strategic initiatives, enhance client solutions, and foster long-term client relationships.
Eighteen early-career clinical investigators to receive year-long mentorship through professional development program led by international thought leaders
